Curevac’s credibility unravels along with its Covid-19 vaccine
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
The big approvals still on the cards for 2021
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Asco 2021 – full Olympia results sweep away Parp doubts
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.
Mitsubishi's Medicago readies for the second wave
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Roche remains big pharma’s biggest R&D spender
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
